CORDIS
EU research results

CORDIS

English EN
Neuroprosthetic interface systems for restoring motor functions

Neuroprosthetic interface systems for restoring motor functions

Objective

The overall concept of the 48-month Integrated Project NEUWalk is focused specifically on Objective ICT-2009.3.9 Microsystems and Smart Miniaturised Systems with particular emphasis to c) Application-specific microsystems and smart miniaturised systems 1) Biomedical S&T objectives. The technological objective of NEUWalk is to develop novel microtechnology, microelectronics, brain decoding algorithms and smart control interfaces that can be flexibly assembled to address neurobiomedical issues that not only impact the quality of life in thousands of individuals throughout Europe, but also create a significant economic burden for European countries. These innovative neurotechnologies will be combined to achieve an integrated cortico-spinal neuroprosthetic interface. The underlying objective in NEUWalk is to restore motor functions in individuals with severe spinal cord injury (SCI) and to establish a more efficient, less invasive and safer strategy to alleviate Parkinson's disease (PD) syndromes. To achieve this ambitious goal, we will capitalize on recent breakthroughs that demonstrate the impressive capacity of spinal cord stimulations to promote the recovery of full weight bearing walking in paralyzed SCI rats and to alleviate severe Parkinsonian symptoms in rodents. Elaboration and validation of the NEUWalk concept will be carried out in rats with SCI and non-human primates with PD. To accelerate the translation towards efficient clinical therapies, preliminary testing will be conducted in humans with SCI. The potential impact of the microtechnology, microelectronics, and treatment paradigms developed in NEUWalk is tremendous. These advances will open avenues for revolutionary clinical applications and will contribute to fill the increasingly wider gap that separates European research on Neuroprosthetics to similar studies conducted in the United States. Beyond SCI and PD, the NEUWalk concepts will fertilize new designs for the treatment of other neurologic disorders.

Coordinator

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Address

Hansastrasse 27c
80686 Munchen

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 419 547

Administrative Contact

Andrea Zeumann (Ms.)

Participants (12)

Sort alphabetically

Sort by EU Contribution

Expand all

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH

Switzerland

EU Contribution

€ 778 385

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Switzerland

EU Contribution

€ 117 673

UNIVERSITAT ZURICH

Switzerland

EU Contribution

€ 951 399

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE

Switzerland

EU Contribution

€ 1 214 846

Inomed Medizintechnik GmbH

Germany

EU Contribution

€ 683 290

INSTITUT FUER MIKROTECHNIK MAINZ GMBH

Germany

EU Contribution

€ 1 057 638

BITTIUM BIOSIGNALS OY

Finland

EU Contribution

€ 815 942

UNIVERSITE VICTOR SEGALEN BORDEAUX II

France

EU Contribution

€ 354 015

UNIVERSITE DE BORDEAUX

France

EU Contribution

€ 206 305

SCUOLA SUPERIORE DI STUDI UNIVERSITARI E DI PERFEZIONAMENTO SANT'ANNA

Italy

EU Contribution

€ 796 340

FINETECH MEDICAL LIMITED

United Kingdom

EU Contribution

€ 236 486

UNIVERSITY COLLEGE LONDON

United Kingdom

EU Contribution

€ 1 168 134

Project information

Grant agreement ID: 258654

Status

Closed project

  • Start date

    1 June 2010

  • End date

    30 November 2014

Funded under:

FP7-ICT

  • Overall budget:

    € 11 356 496

  • EU contribution

    € 8 800 000

Coordinated by:

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Germany